瑞士苏黎世联邦理工学院的研究团队发现，一种鲜为人知的蛋白质GRK2在阿尔茨海默病发病中扮演关键角色。1研究人员在开罗Ain Shams大学医院采集的痴呆和非痴呆患者脑组织样本中，检测到异常大量的无活性GRK2蛋白。1基于这一发现，科研团队开发了一种实验性化合物Compound 10，能够有效阻止GRK2分子聚集。1
在小鼠实验中，Compound 10展现出多重治疗潜力。1该化合物阻止了GRK2分子形成聚集体，使线粒体功能得到改善，并减少了淀粉样β蛋白积累，同时改善了心脏功能并减缓了衰老迹象。1研究成果已发表在《Cell Reports Medicine》期刊上。1
相比之下，现有阿尔茨海默病药物最多只能延缓病程数个月。1研究团队认为，Compound 10通过不同的生物学通路发挥作用，可能与现有药物形成互补而非替代关系。1该研究已获得专利申请，科研团队目前正积极寻找有意参与药物开发的企业合作伙伴。1每项后续实验需要约1.5至2年才能完成并为下一阶段研究奠定基础。1
Researchers at ETH Zurich have identified an abnormal accumulation of inactive GRK2 protein in brain tissue samples from patients with dementia, suggesting a previously underappreciated role for this protein in Alzheimer's disease 1. The discovery was made through examination of tissue samples from both dementia and non-dementia patients at Ain Shams University Hospital in Cairo 1.
Building on this finding, the research team has developed an experimental compound called Compound 10 that blocks GRK2 molecules from forming aggregates 1. In mouse studies, Compound 10 prevented the harmful buildup of these protein clusters, preserved mitochondrial function, and reduced the accumulation of amyloid-beta protein 1. The treatment also improved cardiac function in the animals and reduced signs of aging, including graying of fur 1. The results have been published in Cell Reports Medicine 1.
The therapeutic approach differs fundamentally from existing Alzheimer's treatments, which at best only slow disease progression by several months 1. Because Compound 10 operates through distinct biological pathways, it has the potential to complement rather than replace current medications 1. The research team has filed a patent and is actively seeking companies interested in participating in drug development 1. Each experimental phase typically requires approximately 1.5 to 2 years to reach conclusions and design subsequent studies 1.
评论
还没有评论，欢迎留下第一条。